Biomolecular strategies of bone augmentation in spinal surgery

Trends in Molecular Medicine

Volumn 17, Issue 4, 2011, Pages 215-222

  Pneumaticos, Spyros G ^a   Triantafyllopoulos, Georgios K ^a   Chatziioannou, Sophia ^a   Basdra, Efthimia K ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 9; OSTEOGENIC PROTEIN 1; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

BONE CONDUCTION; BONE GRAFT; BONE MARROW CELL; BONE REGENERATION; DRUG EFFECT; DRUG SAFETY; GENE THERAPY; HUMAN; INTERVERTEBRAL DISK DEGENERATION; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; REVIEW; SPINE FUSION; SPINE SURGERY; THROMBOCYTE RICH PLASMA;

ANIMALS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; BONE TRANSPLANTATION; GENE THERAPY; HUMANS; MESENCHYMAL STEM CELLS; OSTEOGENESIS; PLATELET-RICH PLASMA; SPINAL FUSION; SPINE;

EID: 79954619841     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.12.002     Document Type: Review

References (78)

1. Secco M., et al. Multipotent stem cells from umbilical cord: cord is richer than blood!. Stem Cells 2008, 26:146-150.
2. Yen B.L., et al. Isolation of multipotent cells from human term placenta. Stem Cells 2005, 23:3-9.
3. Deschaseaux F., et al. Bone regeneration: the stem/progenitor cells point of view. J. Cell Mol. Med. 2010, 14:103-115.
4. Pneumaticos S.G., et al. Segmental bone defects: from cellular and molecular pathways to the development of novel biological treatments. J. Cell Mol. Med. 2010, 10.1111/j.1582-4934.2010.01062.x.
5. Stenderup K., et al. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003, 33:919-926.
6. Burns J.S., et al. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. Cancer Res. 2005, 65:3126-3135.
7. Serakinci N., et al. Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell. Regen. Med. 2006, 1:125-131.
8. Abdallah B.M., Kassem M. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther. 2008, 15:109-116.
9. Bianchi G., et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp. Cell Res. 2003, 287:98-105.
10. Ma T., et al. Hypoxia and stem cell-based engineering of mesenchymal tissues. Biotechnol. Prog. 2009, 25:32-42.
11. Delorme B., et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 2009, 27:1142-1151.
12. Uccelli A., et al. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
13. Martinez C., et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007, 109:4245-4248.
14. Gang E.J., et al. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007, 109:1743-1751.
15. Astori G., et al. In vitro and multicolor phenotypic characterization of cell subpopulations identified in fresh human adipose tissue stromal vascular fraction and in the derived mesenchymal stem cells. J. Transl. Med. 2007, 5:55.
16. Aust L., et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy 2004, 6:7-14.
17. Miyazaki M., et al. Comparison of human mesenchymal stem cells derived from adipose tissue and bone marrow for ex vivo gene therapy in rat spinal fusion model. Spine (Phila Pa 1976) 2008, 33:863-869.
18. Miyazaki M., et al. An update on bone substitutes for spinal fusion. Eur. Spine J. 2009, 18:783-799.
19. Minamide A., et al. The use of cultured bone marrow cells in type I collagen gel and porous hydroxyapatite for posterolateral lumbar spine fusion. Spine (Phila Pa 1976) 2005, 30:1134-1138.
20. Wang T., et al. Evaluation of autologous bone marrow mesenchymal stem cell-calcium phosphate ceramic composite for lumbar fusion in rhesus monkey interbody fusion model. Tissue Eng. 2005, 11:1159-1167.
21. Gan Y., et al. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 2008, 29:3973-3982.
22. Fréchette J.P., et al. Platelet-rich plasmas: growth factor content and roles in wound healing. J. Dent. Res. 2005, 84:434-439.
23. Intini G. The use of platelet-rich plasma in bone reconstruction therapy. Biomaterials 2009, 30:4956-4966.
24. Alvarez R.H., et al. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin. Proc. 2006, 81:1241-1257.
25. Lee J.Y., et al. Enhanced bone formation by controlled growth factor delivery from chitosan-based biomaterials. J. Control. Release 2002, 78:187-197.
26. Massagué J., Gomis R.R. The logic of TGFbeta signaling. FEBS Lett. 2006, 580:2811-2820.
27. Dimitriou R., et al. Current concepts of molecular aspects of bone healing. Injury 2005, 36:1392-1404.
28. Komaki H., et al. Repair of segmental bone defects in rabbit tibiae using a complex of beta-tricalcium phosphate, type I collagen, and fibroblast growth factor-2. Biomaterials 2006, 27:5118-5126.
29. Bao P., et al. The role of vascular endothelial growth factor in wound healing. J. Surg. Res. 2009, 153:347-358.
30. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003, 83:835-870.
31. Wang Y., et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J. Clin. Invest. 2007, 117:1616-1626.
32. Kanczler J.M., et al. The effect of the delivery of vascular endothelial growth factor and bone morphogenic protein-2 to osteoprogenitor cell populations on bone formation. Biomaterials 2010, 31:1242-1250.
33. Schipani E., et al. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J. Bone Miner. Res. 2009, 24:1347-1353.
34. Hee H.T., et al. Do autologous growth factors enhance transforaminal lumbar interbody fusion?. Eur. Spine J. 2003, 12:400-407.
35. Jenis L.G., et al. A prospective study of Autologous Growth Factors (AGF) in lumbar interbody fusion. Spine J. 2006, 6:14-20.
36. Lowery G.L., et al. Use of autologous growth factors in lumbar spinal fusion. Bone 1999, 25:47S-50S.
37. Weiner B.K., Walker M. Efficacy of autologous growth factors in lumbar intertransverse fusions. Spine (Phila Pa 1976) 2003, 28:1968-1971.
38. Carreon L.Y., et al. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. Spine (Phila Pa 1976) 2005, 30:E243-E247.
39. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
40. Urist M.R., et al. Solubilized and insolubilized bone morphogenetic protein. Proc. Natl. Acad. Sci. U. S. A. 1979, 76:1828-1832.
41. Sampath T.K., Reddi A.H. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:7599-7603.
42. Reddi A.H., Huggins C. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. Proc. Natl. Acad. Sci. U. S. A. 1972, 69:1601-1605.
43. Wozney J.M., et al. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
44. Aono A., et al. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem. Biophys. Res. Commun. 1995, 210:670-677.
45. Heldin C.H., et al. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
46. Sebald W., et al. Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol. Chem. 2004, 385:697-710.
47. Kaps C., et al. Distinct roles of BMP receptors Type IA and IB in osteo-/chondrogenic differentiation in mesenchymal progenitors (C3H10T1/2). Biofactors 2004, 20:71-84.
48. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
49. Bessa P.C., et al. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J. Tissue Eng. Regen. Med. 2008, 2:1-13.
50. Miyazono K., et al. Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins. Oncogene 2004, 23:4232-4237.
51. Celil A.B., et al. Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. J. Cell Biochem. 2005, 95:518-528.
52. Sowa H., et al. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J. Biol. Chem. 2004, 279:40267-40275.
53. Maeda S., et al. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J. 2004, 23:552-563.
54. Depprich R., et al. [Comparison of the osteogenic activity of bone morphogenetic protein (BMP) mutants]. Mund. Kiefer. Gesichschir. 2005, 9:363-369. [in German].
55. Saito A., et al. Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide. J. Biomed. Mater. Res. A. 2004, 70:115-121.
56. Bessa P.C., et al. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J. Tissue Eng. Regen. Med. 2008, 2:81-96.
57. Blattert T.R., et al. Successful transpedicular lumbar interbody fusion by means of a composite of osteogenic protein-1 (rhBMP-7) and hydroxyapatite carrier: a comparison with autograft and hydroxyapatite in the sheep spine. Spine (Phila Pa 1976) 2002, 27:2697-2705.
58. Boden S.D., et al. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine (Phila Pa 1976) 1999, 24:1179-1185.
59. Bomback D.A., et al. Comparison of posterolateral lumbar fusion rates of Grafton Putty and OP-1 Putty in an athymic rat model. Spine (Phila Pa 1976) 2004, 29:1612-1617.
60. Boden S.D., et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial. Spine (Phila Pa 1976) 2002, 27:2662-2673.
61. Boden S.D., et al. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (Phila Pa 1976) 2000, 25:376-381.
62. Miyazaki M., et al. Comparison of lentiviral and adenoviral gene therapy for spinal fusion in rats. Spine (Phila Pa 1976) 2008, 33:1410-1417.
63. Phillips J.E., et al. Virus-based gene therapy strategies for bone regeneration. Biomaterials 2007, 28:211-229.
64. Ghosh S.S., et al. Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol. 2006, 133:9-29.
65. Nayak S., Herzog R.W. Progress and prospects: immune responses to viral vectors. Gene Ther. 2010, 17:295-304.
66. Sheyn D., et al. Genetically modified mesenchymal stem cells induce mechanically stable posterior spine fusion. Tissue Eng. Part A 2010, 10.1089/ten.tea.2009.0786.
67. Hasharoni A., et al. Murine spinal fusion induced by engineered mesenchymal stem cells that conditionally express bone morphogenetic protein-2. J. Neurosurg. Spine 2005, 3:47-52.
68. Alden T.D., et al. Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. J. Neurosurg. 1999, 90:109-114.
69. Helm G.A., et al. Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J. Neurosurg. 2000, 92:191-196.
70. Bright C., et al. In vivo evaluation of plasmid DNA encoding OP-1 protein for spine fusion. Spine (Phila Pa 1976) 2006, 31:2163-2172.
71. Zhu W., et al. Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J. Bone Miner. Res. 2004, 19:2021-2032.
72. Hidaka C., et al. Enhancement of spine fusion using combined gene therapy and tissue engineering BMP-7-expressing bone marrow cells and allograft bone. Spine (Phila Pa 1976) 2003, 28:2049-2057.
73. Wang J.C., et al. Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J. Bone Joint Surg. Am. 2003, 85-A:905-911.
74. Peterson B., et al. Genetically modified human derived bone marrow cells for posterolateral lumbar spine fusion in athymic rats: beyond conventional autologous bone grafting. Spine (Phila Pa 1976) 2005, 30:283-290.
75. Dumont R.J., et al. Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery 2002, 51:1239-1245.
76. Boden S.D., et al. Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine (Phila Pa 1976) 1998, 23:2486-2492.
77. Viggeswarapu M., et al. Adenoviral delivery of LIM mineralization protein-1 induces new-bone formation in vitro and in vivo. J. Bone Joint Surg. Am. 2001, 83-A:364-376.
78. Lu S.S., et al. The osteoinductive properties of Nell-1 in a rat spinal fusion model. Spine J. 2007, 7:50-60.